脑膜瘤代谢谱分析揭示新的亚组特异性生物学见解与结局依赖性
本研究对代表各分子组和WHO级别的脑膜瘤进行非靶向代谢谱分析,鉴定出560种生化物质,并发现21种代谢物结局特征可强烈预测结局(HR=326.49,95%CI=16.72-6375.48,P<.0001)。N6-三甲基赖氨酸丰度与更短复发时间相关(log-rank P=.009),并在高代谢和WHO 2级肿瘤中经靶向HPLC-MS/MS验证。
要点
- 21种代谢物特征可预测脑膜瘤结局,校正WHO级别、切除程度和辅助放疗后HR=326.49(95%CI=16.72-6375.48,P<.0001)。
- N6-三甲基赖氨酸丰度与全队列更短复发时间相关(log-rank P=.009),并在高代谢和WHO 2级肿瘤中经靶向HPLC-MS/MS验证。
- N6-三甲基赖氨酸丰度与氧化磷酸化通路激活相关,在高代谢亚组中预示更差结局,但在增殖亚组中预示更好结局。
核心结论
- 本研究首次证明N6-三甲基赖氨酸在高代谢脑膜瘤中具有亚组特异性预后作用,利用广泛可及的HPLC-MS/MS技术提供更精细的结局预测。
- 作者提示不同亚组间能量利用偏好存在根本差异,并可能存在亚组特异性治疗的需求。
研究设计与样本
- 对代表各分子组和WHO级别的脑膜瘤进行非靶向代谢谱分析,使用Cox回归鉴定预后生化物质,并通过RNA和蛋白通路分析探索生物学重要性,最后用靶向HPLC-MS/MS验证。
主要发现
- 全局代谢谱分析鉴定出560种独特生化物质。
- 鉴定出21种代谢物结局特征,校正WHO级别、切除程度和辅助放疗后强烈预测结局(HR=326.49,95%CI=16.72-6375.48,P<.0001)。
- N6-三甲基赖氨酸丰度与全队列更短复发时间相关(log-rank P=.009),并在高代谢和WHO 2级肿瘤中具体相关;该结果在两个队列中经靶向HPLC-MS/MS验证。
- 共识RNA和蛋白表达分析显示N6-三甲基赖氨酸丰度与氧化磷酸化通路激活相关,在高代谢亚组中预示更差结局,但在增殖亚组中预示更好结局。
- 上调的丙酮酸和乳酸转运体与增殖性脑膜瘤更差结局具体相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Our group and others have recently identified four molecular groups of meningioma, with unique underlying biology and outcomes. The relevance of group-specific metabolite profiles (particularly among hypermetabolic tumors), has not been explored. METHODS: We performed untargeted metabolic profiling of meningiomas representing each molecular group and World Health Organization (WHO) grade. Prognostic biochemicals were identified using Cox regression and their biological importance was explored using RNA and protein-based pathway analyses. Validation was performed using targeted high performance liquid chromatography-mass spectrometry (HPLC-MS/MS). RESULTS: Global metabolic profiling identified 560 unique biochemicals. We identified a 21-metabolite outcome signature which is strongly predictive of outcome after adjusting for WHO grade, extent of resection, and receipt of adjuvant radiotherapy (HR = 326.49, 95% CI = 16.72-6375.48, P < .0001). The abundance of N6-trimethyllysine was associated with earlier time to recurrence on our whole cohort (log-rank P = .009) and within hypermetabolic and WHO grade 2 tumors specifically; this was validated using targeted HPLC-MS/MS on two cohorts. Consensus RNA and protein expression analysis demonstrated as association between N6-trimethyllysine abundance and activation of oxidative phosphorylation pathways, which portended worse outcomes in the hypermetabolic subgroup but, interestingly, better outcomes in the proliferative subgroup. By contrast, upregulated pyruvate and lactate transporters were associated with worse outcomes in proliferative meningiomas specifically. CONCLUSIONS: This is the first study to demonstrate a subgroup-specific prognostic role of N6-trimethyllysine in hypermetabolic meningiomas, offering increasingly granular outcome predictions using a widely accessible technique (HPLC-MS/MS). We also suggest fundamental differences in preferred energy utilization between and a potential need for subgroup-specific therapies.
引用
- Landry AP, Wang JZ, Yefet LS, et al. Metabolic profiling of meningioma reveals novel subgroup-specific biologic insights and outcome dependencies. Neuro Oncol. 2025. PMID: 39851181. doi:10.1093/neuonc/noae281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。